Training activity information
Details
Interpret data from all local HLA typing tests using current nomenclature
Type
Entrustable training activity (ETA)
Evidence requirements
Evidence the activity has been undertaken by the trainee repeatedly, consistently, and effectively over time, in a range of situations. This may include occasions where the trainee has not successfully achieved the outcome of the activity themselves. For example, because it was not appropriate to undertake the task in the circumstances or the trainees recognised their own limitations and sought help or advice to ensure the activity reached an appropriate conclusion.
Reflection at multiple timepoints on the trainee learning journey for this activity.
Considerations
- Local procedures
- Internal quality controls and external quality assessment measures
- HLA nomenclature
- National and international standards for reporting of HLA types
- Interpretation software
- Factors influencing interpretation of HLA typing data
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
What does success look like?
- Identify what is expected of you in relation to accurately interpreting raw HLA typing data and assigning genotypes using current, standardized nomenclature.
- Consider how the learning outcomes apply, specifically in relation to interpreting test results and practicing in accordance with quality standards.
- Discuss with your training officer to gain clarity of what is expected of you in relation to resolving data ambiguities, identifying the appropriate allele resolution, and applying the correct nomenclature structure (e.g., four-field reporting).
What is your prior experience of this activity?
- Think about what you already know about interpreting sequence traces or probe data, principles of HLA inheritance, and general biological nomenclature rules.
- Consider possible challenges you might face during the activity, such as encountering ambiguous allele combinations, interpreting noise or low-quality signals, or finding rare alleles not easily resolved by routine software.
- Recognise the scope of your own practice for this activity i.e. know when you will need to seek advice or help, and from whom. You will need to seek advice from your Training Officer when required, for example if the result remains ambiguous after all local troubleshooting and reconciliation steps, requiring confirmation on whether further testing is warranted.
- Acknowledge how you feel about the responsibility of translating complex raw data into clinically actionable genetic information.
What do you anticipate you will learn from the experience?
- Consider the specific skills you want to develop, such as methodical review of raw data for quality control or precise application of HLA nomenclature rules.
- Identify the specific insights you hope to gain into how different molecular techniques influence the potential for data ambiguity.
What additional considerations do you need to make?
- Consult actions identified following previous experiences of data interpretation or using specialised software.
- Identify important information you need to consider before embarking on the activity, such as reviewing the latest HLA nomenclature updates, standard operating procedures for ambiguity resolution and common HLA alleles and polymorphism.
In action
Is anything unexpected occurring?
- Are you noticing anything surprising or different from what you anticipate whilst interpreting the HLA typing data?
- Are you encountering situations such as:
- The raw data containing ambiguities or unexpected patterns that make allele assignment challenging or suggest a discrepancy?
- The interpretation software yielding unexpected challenges, such as conflicting allele assignments or errors in applying current nomenclature?
- The result suggesting a rare allele or complex, novel genotype that you have not encountered previously?
How are you reacting to the unexpected development?
- How is this impacting your actions? For example, are you responding to the situation appropriately? Are you adapting or changing your approach to resolving the ambiguity?
- Consider the steps you are taking in the moment, such as:
- Immediately reviewing the raw data traces manually to verify the software’s initial assignment and checking multiple sequence reads
- Consulting the current official HLA nomenclature database or expert references to verify a rare or complex genotype
- How are you feeling in that moment? For instance, are you finding it difficult to reconcile conflicting results from different analysis tools? Is it affecting your confidence in finalising the report independently?
What is the conclusion or outcome?
- Identify how you are working within your scope of practice. For example, are you successfully applying standardised nomenclature to resolve a common ambiguity using departmental SOPs? Or are you needing support because the potential discovery of a novel allele requires senior pathological verification and specialised reporting?
- What are you learning as a result of the unexpected development? For example, are you mastering a systematic approach for ambiguity resolution in molecular typing? Or gaining insight into the structure and application of current HLA nomenclature?
On action
What happened?
- Begin by summarising the key steps you took when interpreting HLA typing data.
- Consider specific events, actions, or interactions which felt important, such as how you resolved a sequence ambiguity (e.g., heterozygous site) or assigned the final allele using the four-field nomenclature.
- Include any ‘reflect-in-action’ moments where you had to adapt to the situation as it unfolded, for instance, immediately consulting the official nomenclature database when faced with a rare or complex allele combination or performing a manual review of sequence traces when software assignment was equivocal.
- How did you feel during this experience, e.g., did you feel focused on accuracy or challenged by complex nomenclature rules?
How has this experience contributed to your developing practice?
- Identify what learning you can take from this experience regarding interpreting complex HLA typing data and using current nomenclature. What strengths did you demonstrate, e.g., systematic review of raw data?
- What skills and/or knowledge gaps were evident, e.g., knowledge of advanced nomenclature rules for null/truncated alleles?
- Compare this experience against previous engagement with similar activities – were any previously identified actions for development achieved? Has your practice improved in interpreting test results?
- Identify any challenges you experienced, such as ambiguous results, nomenclature application, or needing advice on resolving data conflicts with expected genotypes, and how you reacted to this.
What will you take from the experience moving forward?
- Identify the actions or ‘next steps’ you will now take to support the assimilation of what you have learnt, including from any feedback you have received, with regards to enhancing your interpretation skills and knowledge of HLA nomenclature.
- What will you do differently next time you approach HLA typing data interpretation, for instance, by proactively checking the resolution level (e.g., G vs P groups) before final assignment?
- Do you need to practise any aspect of the activity further, such as ambiguity resolution algorithms or key learning outcomes related to practicing in accordance with quality standards?
Beyond action
Have you revisited the experiences?
- How have your subsequent experiences of interpreting HLA typing data since completing this specific training activity led you to revisit your initial approach or decisions during that activity? For example, how a subsequent case requiring the resolution of a complex sequence ambiguity forced you to re-evaluate the rigour of your systematic review and the application of HLA nomenclature during your first attempt at this training activity.
- Considering what you understand about HLA nomenclature rules, ambiguity resolution, and the clinical implications of resolution level now, were the actions or considerations you identified after your initial reflection on this training activity sufficient?
- How have you since implemented or adapted improvements in your interpretation process or application of current nomenclature based on further learning and experiences? For example, how you proactively implemented a mandatory check against the latest HLA nomenclature updates for rare alleles based on further learning.
- Has discussing common interpretation challenges or the application of current nomenclature rules with colleagues, peers, or supervisors changed how you now view your initial experience in this training activity? For example, how professional storytelling with a senior colleague about a time when an ambiguous genotype was misclassified due to nomenclature misunderstanding refined your understanding of the critical nature of applying complex rules during result interpretation.
How have these experiences impacted upon current practice?
- How has the learning from this initial training activity, in combination with subsequent experiences of interpreting HLA typing data, contributed to your overall confidence and competence in accurately interpreting raw data into clinically relevant HLA types, particularly in preparing for observed assessments (DOPS or OCEs) such as ‘Interpret HLA sequence data’? For example, how your accumulated ability in data analysis and pattern recognition now enables you to resolve complex ambiguities confidently during a DOPS assessment.
- How has reflecting back on this specific training activity, combined with everything you’ve learned since, shaped your current approach to data interpretation and nomenclature application?
- How does this evolved understanding help you identify when data interpretation is complex or falls outside standard protocols and when this requires expert review? For example, how your evolved approach means you now routinely seek expert review immediately when a novel or extremely rare genotype is suspected, recognising this requires senior pathological input.
- Looking holistically at your training journey, how has this initial data interpretation experience, revisited with your current perspective, contributed to your development in meeting the learning outcomes related to interpreting test results and practicing in accordance with quality standards? For example, how this foundational experience has supported your development in transferable skills such as application of complex rules and critical evaluation of results that will be valuable in future roles or responsibilities.
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 4 |
Outcome
Interpret test results for the range of techniques performed. |
| # 6 |
Outcome
Practice in accordance with quality and accreditation standards. |